Short answer
Inhibikase Therapeutics, Inc. (IKT) filed an 8-K current report with the SEC on September 8, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Exhibit 99.1 furnished under Regulation FD, but not deemed filed under Exchange Act Section 18.
Inhibikase Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Exhibit 99.1 furnished under Regulation FD, but not deemed filed under Exchange Act Section 18
- Disclosure generally excluded from incorporation by reference into other SEC filings unless expressly referenced
Item EX-99.1 · Exhibit EX-99.1
- Phase 3 IMPROVE-PAH enrolling across 26 countries and 46 of 180 planned sites, validating late-stage execution
- IKT-001 targets PAH, a disease with approximately 30% five-year mortality and an estimated $8.3B antiproliferative market
- Prior imatinib data showed 45-meter placebo-adjusted 6MWD improvement at higher dosing and a 32% PVR reduction
- Twelve-week titration and prodrug design target imatinib’s GI tolerability and discontinuation limitations
- Key catalysts: interim safety readout in 1H 2027, PVR data in mid-2028, and 6MWD topline data in mid-2029
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Inhibikase Therapeutics, Inc. 8-K filings
Get the next IKT 8-K as it lands
Follow IKT for push alerts, or ask the research agent what this filing means.